FDA panel narrowly supports approval of maintenance olaparib in BRCA -mutated pancreatic cancer

An FDA panel today supported approval of olaparib as maintenance treatment for adults with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer.The final vote of 7-5 by the Oncologic Drug Advisory Committee reflected concerns of some panelists who sought more survival data and questioned whether olaparib (Lynparza; AstraZeneca, Merck), a first-in-class

Read the full article here

Related Articles